Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$637M |
| 2 |
Weyerhaeuser
WY
|
+$340M |
| 3 |
IQVIA
IQV
|
+$132M |
| 4 |
Halliburton
HAL
|
+$123M |
| 5 |
Dover
DOV
|
+$112M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Invesco QQQ Trust
QQQ
|
+$3.68B |
| 2 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$708M |
| 3 |
State Street Health Care Select Sector SPDR ETF
XLV
|
+$460M |
| 4 |
RAI
Reynolds American Inc
RAI
|
+$293M |
| 5 |
Gilead Sciences
GILD
|
+$246M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 6.22% |
| 2 | Healthcare | 5.12% |
| 3 | Financials | 4.53% |
| 4 | Consumer Discretionary | 4.09% |
| 5 | Communication Services | 3.16% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CRCM
3976
DELISTED
CARE.COM, INC.
CRCM
| $316K | ﹤0.01% |
19,912
+8,303
| +72% | +$123K |
|
3977
Hope Bancorp
HOPE
$1.79B
| $315K | ﹤0.01% |
17,793
-7,692
| -30% | -$131K |
|
|
HA
3978
CALL
DELISTED
Hawaiian Holdings, Inc.
HA
| $315K | ﹤0.01% |
8,400
+300
| +4% | +$12.7K |
|
3979
PUT
GATX Corp
GATX
$6.27B
| $314K | ﹤0.01% |
5,100
+5,000
| +5,000% | +$308K |
|
3980
Kemper
KMPR
$1.71B
| $314K | ﹤0.01% |
5,920
+1,040
| +21% | +$47.4K |
|
3981
Vanguard Consumer Discretionary ETF
VCR
$6.33B
| $314K | ﹤0.01% |
2,188
+138
| +7% | +$19.6K |
|
|
ACHN
3982
DELISTED
Achillion Pharmaceuticals
ACHN
| $313K | ﹤0.01% |
69,669
+4,754
| +7% | +$21.1K |
|
3983
PUT
PACCAR
PCAR
$69.7B
| $311K | ﹤0.01% |
6,450
-3,300
| -34% | -$149K |
|
|
RAD
3984
DELISTED
Rite Aid Corporation
RAD
| $311K | ﹤0.01% |
7,936
-1,990
| -20% | -$94.3K |
|
|
ADSW
3985
DELISTED
Advanced Disposal Services Inc
ADSW
| $311K | ﹤0.01% |
12,315
-16,463
| -57% | -$390K |
|
3986
PUT
Hecla Mining
HL
$11.2B
| $310K | ﹤0.01% |
61,800
-8,700
| -12% | -$44.6K |
|
3987
CALL
Invesco DB Agriculture Fund
DBA
$1.24B
| $309K | ﹤0.01% |
16,300
-12,300
| -43% | -$237K |
|
3988
Ducommun
DCO
$2.96B
| $309K | ﹤0.01% |
9,660
-1,850
| -16% | -$55.1K |
|
|
ADAP
3989
DELISTED
Adaptimmune Therapeutics
ADAP
| $308K | ﹤0.01% |
+37,600
| New | +$235K |
|
3990
LPL Financial
LPLA
$28.3B
| $308K | ﹤0.01% |
5,958
-8,447
| -59% | -$389K |
|
3991
Bio-Rad Laboratories Class A
BIO
$9.27B
| $307K | ﹤0.01% |
1,380
-2,917
| -68% | -$656K |
|
3992
Editas Medicine
EDIT
$442M
| $307K | ﹤0.01% |
12,803
+12,546
| +4,882% | +$239K |
|
3993
Bank of N.T. Butterfield & Son
NTB
$2.44B
| $307K | ﹤0.01% |
8,362
-238
| -3% | -$8.12K |
|
3994
TG Therapeutics
TGTX
$7.6B
| $307K | ﹤0.01% |
25,921
-28,156
| -52% | -$321K |
|
|
BGG
3995
DELISTED
Briggs & Stratton Corp.
BGG
| $307K | ﹤0.01% |
13,090
-2,770
| -17% | -$62.9K |
|
|
STRP
3996
CALL
DELISTED
Straight Path Communications Inc.
STRP
| $307K | ﹤0.01% |
1,700
-19,400
| -92% | -$3.48M |
|
3997
PUT
Signet Jewelers
SIG
$3.71B
| $306K | ﹤0.01% |
4,600
+1,900
| +70% | +$117K |
|
3998
Zurn Elkay Water Solutions
ZWS
$8.54B
| $306K | ﹤0.01% |
24,999
+2,126
| +9% | +$24.6K |
|
3999
Badger Meter
BMI
$4.05B
| $305K | ﹤0.01% |
6,221
-339
| -5% | -$15.1K |
|
4000
ONE Gas
OGS
$5.03B
| $304K | ﹤0.01% |
4,133
+286
| +7% | +$21K |
|
Similar funds
Barclays's Q3 2017 Portfolio in Review
As of Q3 2017, Barclays held 7,380 positions worth $97.1B, up 4% from $93.4B the previous quarter. Its ten largest holdings account for 29% of the portfolio.
Barclays's Q3 2017 filing shows 424 new, 3,249 increased, 2,816 reduced and 405 closed positions. Its largest new stake was Crown Castle International Corp. 6.875% Mandatory Convertible Preferred Stock, Series A: 39,656 shares worth $42.4M. The largest sale was Invesco QQQ Trust, an estimated $3.68B.
By sector, the portfolio is most concentrated in Technology at 6.2% of assets, up from 6.1% a quarter earlier, followed by Healthcare and Financials.
- Barclays's largest Q3 2017 buy was Crown Castle International Corp. 6.875% Mandatory Convertible Preferred Stock, Series A: 39,656 shares worth $42.4M.
- Barclays added most to State Street SPDR S&P 500 ETF Trust in Q3 2017, an estimated $637M increase.
- Barclays's biggest Q3 2017 reduction was Invesco QQQ Trust, cutting an estimated $3.68B.
- Barclays fully exited Reynolds American Inc in Q3 2017, selling an estimated $293M.
- Barclays's ten largest holdings make up 29% of its $97.1B portfolio in Q3 2017.
- Barclays opened 424 new positions and closed 405 in Q3 2017.
- Barclays's portfolio value rose 4% quarter-over-quarter to $97.1B.
Based on Barclays's 13F filing for Q3 2017, filed 14 Nov 2017.